Compounded Tirzepatide vs Zepbound
Cost, Legality & Safety — What Changed After the Shortage Ended (2026)
Compounded tirzepatide and brand-name Zepbound contain the same dual GLP-1/GIP molecule, but they differ in FDA regulatory status, pricing ($200-500/month vs $1,000+), and quality controls. This comparison covers the legal landscape after the tirzepatide shortage ended, pharmacy standards (503A vs 503B), and how to evaluate safety.
Compounded Tirzepatide vs Zepbound: At a Glance
Compounded Tirzepatide
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
Zepbound
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
Detailed Comparison
| Feature | Compounded Tirzepatide | Zepbound |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Dosing | 2.5-15 mg SC weekly | 2.5-15 mg SC weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Half-life | ~5 days | ~5 days |
| FDA Status | FDA-approved: Mounjaro (T2D), Zepbound (obesity) | FDA-approved: Mounjaro (T2D), Zepbound (obesity) |
| Key Trial | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss |
| Side Effects | Nausea (31%), vomiting, diarrhea, constipation | Nausea (31%), vomiting, diarrhea, constipation |
Which Should You Choose?
Tirzepatide (dual gip/glp-1 receptor agonist) and Tirzepatide (dual gip/glp-1 receptor agonist) serve different clinical roles despite both being in the Dual GIP/GLP-1 agonist space. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Track Both in Shotlee
Shotlee supports tracking any medication or peptide. Compare your results across different protocols with clean dose logs and outcome data.
Making an Informed Choice Between Compounded Tirzepatide and Zepbound
Choosing between Compounded Tirzepatide and Zepbound depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Compounded Tirzepatide and Zepbound is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Compounded Tirzepatide vs Zepbound: Common Questions
Tirzepatide is a dual gip/glp-1 receptor agonist while Tirzepatide is a dual gip/glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Tirzepatide works as a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly), while Tirzepatide is a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly). They have different half-lives (~5 days vs ~5 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
References
- [1]Clinical TrialJastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." N Engl J Med. 2022;387(3):205-216.
- [2]FDAU.S. Food and Drug Administration. "FDA Approves Tirzepatide for Chronic Weight Management." FDA News Release. November 8, 2023.
- [3]Clinical TrialGarvey WT, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." Lancet. 2023;402(10402):613-626.
- [4]FDAU.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." Updated 2023.
Track Compounded Tirzepatide or Zepbound in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
🚀 Use Shotlee for Free